Type II Diabetes. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: Each Capsule contains 800 mg of decaffeinated green coffee extract and 50 percent chlorogenic acid . Two Capsules daily, one a half hour before breakfast and anothe
Treatment - Drugs
Placebo
Intervention group: Each Capsule contains 800 mg of decaffeinated green coffee extract and 50 percent chlorogenic acid . Two Capsules daily, one a half hour before breakfast and another a half hour be
Control group: Each Capsule contains 800 mg of celloluse. Two Capsules daily, one a half hour before breakfast and another a half hour before lunch with a full glass of water.
Sponsors
Vice chancellor for research, Fasa University of Medical Sciences
Vice chancellor for research, Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: diagnosis of type II diabetes during the last two years, aged 45 to 60 years, no weight loss during the last 6 months (less than 1 kg), avoiding the use of tobacco and alcohol Exclusion criteria: any change in medications or supplements, pregnancy, chronic kidney and liver disease, neuromuscular disease, failure to follow the prescribed diet (if food records during the study show the energy intake of 300 calories less or more than the amount specified).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2HPP. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;FBS. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;Weight. Timepoint: Beginning and end of each phase. Method of measurement: Carriage scales.;Fetuin-A. Timepoint: Beginning and end of each phase. Method of measurement: ELISA.;TG. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;Chol. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;LDL. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;HDL. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;Insolin. Timepoint: Beginning and end of each phase. Method of measurement: ELISA.;HOMA-IR. Timepoint: Beginning and end of each phase. Method of measurement: Formola.;GOT. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;GPT. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;ALK. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;Pr. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;ALB. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;Total billirobin. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;Direct billirobin. Timepoint: Beginning and end of each phase. Method of measurement: Biochemical auto analyzer colorimetric method.;Blood pressure. Timepoint: Beginning and end of each phase. Method of measurement: | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzad Roshanzamir
Fasa University of Medical Sciences
Outcome results
None listed